Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 2 |
2018 | 1 |
2021 | 1 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Exon-Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation.
Noncoding RNA. 2021 Apr 16;7(2):26. doi: 10.3390/ncrna7020026.
Noncoding RNA. 2021.
PMID: 33923420
Free PMC article.
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
Bohnacker T, Prota AE, Beaufils F, Burke JE, Melone A, Inglis AJ, Rageot D, Sele AM, Cmiljanovic V, Cmiljanovic N, Bargsten K, Aher A, Akhmanova A, Díaz JF, Fabbro D, Zvelebil M, Williams RL, Steinmetz MO, Wymann MP.
Bohnacker T, et al. Among authors: cmiljanovic n.
Nat Commun. 2017 Mar 9;8:14683. doi: 10.1038/ncomms14683.
Nat Commun. 2017.
PMID: 28276440
Free PMC article.
Item in Clipboard
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
Janku F, Choong GM, Opyrchal M, Dowlati A, Hierro C, Rodon J, Wicki A, Forster MD, Blagden SP, Yin J, Reid JM, Muller H, Cmiljanovic N, Cmiljanovic V, Adjei AA.
Janku F, et al. Among authors: cmiljanovic n.
Cancers (Basel). 2024 Mar 13;16(6):1137. doi: 10.3390/cancers16061137.
Cancers (Basel). 2024.
PMID: 38539472
Free PMC article.
Item in Clipboard
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
Beaufils F, Cmiljanovic N, Cmiljanovic V, Bohnacker T, Melone A, Marone R, Jackson E, Zhang X, Sele A, Borsari C, Mestan J, Hebeisen P, Hillmann P, Giese B, Zvelebil M, Fabbro D, Williams RL, Rageot D, Wymann MP.
Beaufils F, et al. Among authors: cmiljanovic n.
J Med Chem. 2017 Sep 14;60(17):7524-7538. doi: 10.1021/acs.jmedchem.7b00930. Epub 2017 Sep 1.
J Med Chem. 2017.
PMID: 28829592
Free PMC article.
Item in Clipboard
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R.
Wicki A, et al. Among authors: cmiljanovic n.
Eur J Cancer. 2018 Jun;96:6-16. doi: 10.1016/j.ejca.2018.03.012. Epub 2018 Apr 13.
Eur J Cancer. 2018.
PMID: 29660598
Clinical Trial.
Item in Clipboard
Cite
Cite